Claims for Patent: 5,847,153

Summary for Patent: 5,847,153

Title:	.beta.-sulfonyl hydroxamic acids
Abstract:	The present invention provides a compound of formula I ##STR1## or pharmaceutical acceptable salts thereof wherein R.sub.1 is C.sub.4-12 alkyl, C.sub.4-12 alkenyl, C.sub.4-12 alkynyl, --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl, --(CH.sub.2).sub.h -aryl, or --(CH.sub.2).sub.h -het; R.sub.2 is C.sub.1-12 alkyl, C.sub.2-12 alkenyl, C.sub.2-12 alkynyl, --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl, --(CH.sub.2).sub.h -C.sub.3-8 cycloalkenyl, --(CH.sub.2).sub.h -aryl, --(CH.sub.2).sub.h -het, --(CH.sub.2).sub.h -Q, --(CH.sub.2).sub.i -X-R.sub.4, or --(CH.sub.2).sub.i CHR.sub.5 R.sub.6. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation.
Inventor(s):	Warpehoski; Martha A. (Portage, MI), Harper; Donald E. (Plainwell, MI)
Assignee:	Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:	08/934,408
Patent Claims:	1. A compound of formula I or pharmaceutical acceptable salts thereof wherein: R.sub.1 is a) C.sub.4-12 alkyl, b) C.sub.4-12 alkenyl, c) C.sub.4-12 alkynyl, d) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl, e) --(CH.sub.2).sub.h -aryl, f) --(CH.sub.2).sub.h -aryl substituted with C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, --NO.sub.2, --CF.sub.3, --CN, or --N(C.sub.1-4 alkyl).sub.2, g) --(CH.sub.2).sub.h -het, or h) --(CH.sub.2).sub.h -het substituted with C.sub.1-4 alkyl, or halo; R.sub.2 is a) C.sub.1-12 alkyl, b) C.sub.1-12 alkyl substituted with one to three halo, --CN, --NO.sub.2, --CF.sub.3, --N(R.sub.3).sub.2, --SR.sub.3, or OH, c) C.sub.2-12 alkenyl, d) C.sub.2-12 alkenyl substituted with one to three halo, --CN, --NO.sub.2, or --CF.sub.3, e) C.sub.2-12 alkynyl, f) C.sub.2-12 alkynyl substituted with one to three halo, --CN, --NO.sub.2, or --CF.sub.3, g) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl, h) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo, i) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkenyl, j) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkenyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo, k) --(CH.sub.2).sub.h -aryl, l) --(CH.sub.2).sub.h -aryl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, --CF.sub.3 --OH, --NO.sub.2, --CN, --N(R.sub.3).sub.2, --SR.sub.3, --SO.sub.2 (C.sub.1-4 alkoxy), --C(.dbd.O)R.sub.3, or --NC(.dbd.O)R.sub.3, m) --(CH.sub.2).sub.h -aryl substituted with one to five halo, n) --(CH.sub.2).sub.h -het, o) --(CH.sub.2).sub.h -het substituted with one to two C.sub.1-4 alkyl, or halo, p) --(CH.sub.2).sub.h -Q, q) --(CH.sub.2).sub.h -Q substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, or phenyl, r) --(CH.sub.2).sub.i -X-R.sub.4, optionally the --(CH.sub.2).sub.i - chain can be substituted with C.sub.1-4 alkyl or phenyl, which in turn can be substituted with one to three halo or C.sub.1-4 alkyl, or s) --(CH.sub.2).sub.i CHR.sub.5 R.sub.6 ; R.sub.3 is a) H, b) C.sub.1-4 alkyl, c) --(CH.sub.2).sub.h -phenyl, or d) --(CH.sub.2).sub.h -phenyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo; X is a) --O--, b) --S(.dbd.O).sub.j -, c) --NR.sub.7 -, d) --S(.dbd.O).sub.2 NR.sub.8 -, or e) --C(.dbd.O)--; R.sub.4 is a) H, b) C.sub.1-4 alkyl, c) --(CH.sub.2).sub.h -phenyl, d) --(CH.sub.2).sub.h -phenyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, --NO.sub.2, or --CN, or e) --(CH.sub.2).sub.h -het; R.sub.5 is a) C.sub.1-4 alkyl, or b) --C(.dbd.O)R.sub.3 ; R.sub.6 is a) --C(.dbd.O)R.sub.3, or b) --(CH.sub.2).sub.h C(.dbd.O)R.sub.3 ; R.sub.7 is a) H, b) C.sub.1-4 alkyl, c) --(CH.sub.2).sub.h -phenyl, d) --(CH.sub.2).sub.h -phenyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo, e) --C(.dbd.O)--R.sub.3, f) --S(.dbd.O).sub.2 R.sub.3, or g) --C(.dbd.O)OR.sub.3 ; R.sub.8 is a) C.sub.1-4 alkyl, b) --(CH.sub.2).sub.h -phenyl, or c) --(CH.sub.2).sub.h -phenyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo; aryl is monocarbocyclic, or bicarbocyclic aromatic moiety; het is 5- to 10-membered unsaturated heterocyclic moiety having one to three atoms selected from the group consisting of oxygen, nitrogen, and sulfur; Q is 5- to 10-membered saturated heterocyclic moiety having one to two atoms selected from the group consisting of oxygen, nitrogen, and sulfur; h is 0, 1, 2, 3, 4, 5, or 6; i is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; and j is 0, 1, or 2. 2. A compound of formula I according to claim 1 wherein R.sub.2 is a) C.sub.1-12 alkyl substituted with one to three halo, --CN, --NO.sub.2, --CF.sub.3, --N(R.sub.3).sub.2, --SR.sub.3, or OH, b) C.sub.2-12 alkenyl, c) C.sub.2-12 alkenyl substituted with one to three halo, --CN, --NO.sub.2, or --CF.sub.3, d) C.sub.2-12 alkynyl, e) C.sub.2-12 alkynyl substituted with one to three halo, --CN, --NO.sub.2, or --CF.sub.3, f) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo, g) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkenyl, h) --(CH.sub.2).sub.h -C.sub.3-8 cycloalkenyl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo, i) aryl, j) aryl substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, --CF.sub.3 --OH, --NO.sub.2, --CN, --N(R.sub.3).sub.2, --SR.sub.3,--SO.sub.2 (C.sub.1-4 alkoxy), --C(.dbd.O)R.sub.3, or --NC(.dbd.O)R.sub.3, k) --(CH.sub.2).sub.h -het, l) --(CH.sub.2).sub.h -het substituted with one to two C.sub.1-4 alkyl, or halo, m) --(CH.sub.2).sub.i -Q, n) --(CH.sub.2).sub.i -Q substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, or phenyl, o) --(CH.sub.2).sub.i -X-R.sub.4, optionally the --(CH.sub.2).sub.i - chain can be substituted with C.sub.1-4 alkyl or phenyl, which in turn can be substituted with one to three halo or C.sub.1-4 alkyl, or p) --(CH.sub.2).sub.h CHR.sub.5 R.sub.6 ; wherein R.sub.3, X, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, aryl, het and Q are as defined as in claim 1; h is 0, 1, 2, 3, 4, 5, or 6; and i is 1, 2, 3, 4, 5 or 6. 3. A compound of formula I according to claim 1 wherein R.sub.2 is a) --(CH.sub.2).sub.h -het, b) --(CH.sub.2).sub.h -het substituted with one to two C.sub.1-4 alkyl, or halo, c) --(CH.sub.2).sub.i -Q, d) --(CH.sub.2).sub.i -Q substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, halo, or phenyl, or e) --(CH.sub.2).sub.i -X-R.sub.4, optionally the --(CH.sub.2).sub.i - chain can be substituted with C.sub.1-4 alkyl or phenyl, which in turn can be substituted with one to three halo or C.sub.1-4 alkyl; wherein X, R.sub.4, R.sub.7, R.sub.8, aryl, het and Q are as defined as in claim 1; h is 0, 1, 2, 3, 4, 5, or 6; and i is 1, 2, 3, 4, 5 or 6. 4. A compound of formula I according to claim 1 wherein R.sub.1 is a) C.sub.4-8 alkyl, b) --(CH.sub.2).sub.h -phenyl, or c) --(CH.sub.2).sub.h -phenyl substituted with C.sub.1-4 alkyl, C.sub.1-4 alkoxy, fluoro, chloro, or bromo; R.sub.2 is a) --(CH.sub.2).sub.h -pyridyl, quinolinyl, pyrrolyl, thienyl, or thiazolyl, or indolyl, which can optionally be substituted with one to three C.sub.1-4 alkyl, C.sub.1-4 alkoxy, phenyl, fluoro, chloro, or bromo; b) --(CH.sub.2).sub.h -piperdinyl, piperazinyl, morpholino, 4-thiomorpholinyl, butyrolactamyl, 2-oxo-oxazolidinyl, or 2,4-dioxo-imidazolidinyl, which can optionally be substituted with one to three C.sub.1-4 alkyl, phenyl, fluoro, chloro, or bromo; c) --(CH.sub.2).sub.i -X-R.sub.4 ; X is a) --S(.dbd.O).sub.j --, R.sub.4 is a) C.sub.1-8 alkyl, b) phenyl, or c) phenyl substituted with C.sub.1-4 alkyl, C.sub.1-4 alkoxy, or halo; h is 0, 1, 2, 3, 4, 5 or 6; i is 1, 2, 3, 4, 5 or 6; and j is 0, 1 or 2. 5. A compound of claim 1 wherein R.sub.1 is selected from the group consisting of n-butyl, isobutyl, 1-methylpropyl, tert-butyl, n-pentyl, 3-methybutyl, n-hexyl, n-heptyl, n-octyl, phenyl, 4-methylphenyl, 4-ethylphenyl, 4-tert-butylphenyl, 4-chlorophenyl, 4-isopropylphenyl, 4-bromophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 4-methoxyphenyl, 4-ethoxyphenyl, 4-n-butoxyphenyl, benzyl, 4-phenylbenzyl, 2-, 3-, or 4-fluorobenzyl, 2-, 3-, 4-chlorobenzyl, 2-, 3-, 4-bromobenzyl, and 4-ethoxybenzyl. 6. A compound of claim 1 wherein R.sub.1 is selected from the group consisting of n-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, phenyl, 4-methylphenyl, 4-ethylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-methoxyphenyl, 4-n-butoxyphenyl, benzyl, 4-fluorobenzyl, 4-chlorobenzyl, 4-bromobenzyl, and 4-ethoxybenzyl. 7. A compound of claim 1 wherein R.sub.2 is selected from the group consisting of methyl, 1-cyano-1-phenyl methyl, 2-cyano ethyl, 2-phenylethyl, 2-bromo-2-phenylethyl, 2-bromoethyl, propyl, isopropyl, 3-chloropropyl, 3-bromopropyl, n-butyl, isobutyl, 3-methylbutyl, 1-methylpropyl, tert-butyl, n-pentyl, 3-methybutyl, n-hexyl, n-heptyl, n-octyl, n-hexadecyl, n-octadecyl, 2-propenyl, 2-propynyl, 3-butenyl, 4-pentenyl, 3-butenynyl, 4-pentenynyl, cyclopentyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 4-cyclohexylbutyl, dimethylaminoethyl, dimethylaminopropyl, diethylaminopropyl, phenylaminomethyl, phenyl, 4-methylphenyl, 4-chlorophenyl, 4-bromophenyl, 4-fluorophenyl, 4-trifluoromethylphenyl, 2-methoxyphenyl, 4-methoxyphenyl, 4-nitrophenyl, 4-ethoxyphenyl, benzyl, 4-methylbenzyl, 2-fluorobenzyl, 3-fluorobenzyl, 4-fluorobenzyl, 2-chlorobenzyl, 3-chlorobenzyl, 4-chlorobenzyl, 2-bromobenzyl, 3-bromobenzyl, 4-bromobenzyl, and 2-methylbenzyl, 3-methylbenzyl, 4-methylbenzyl, 4-ethoxybenzyl, 4-nitrobenzyl, methylcarbonyl, 1-methylcarbonyl methyl, 2-phenylcarbonyl ethyl, isopropylcarbonyl, methoxycarbonyl, ethoxycarbonyl, 1,1-ethoxycarbonyl methyl, 2,2-ethoxycarbonyl ethyl, 1,2-ethoxycarbonyl ethyl, 2-methoxycarbonyl propyl, 3-methoxycarbonyl propyl, 1-ethoxycarbonyl methyl, 1-ethoxycarbonyl ethyl, phenylcarbonyl, phenylcarbonyl methyl, pyridylcarbonyl methyl, pyridylmethyl, pyridylethyl, quinolinylmethyl, pyrrolyl methyl, indolyl methyl, thienyl, thiazolyl, thienylmethyl, thienylethyl, piperdinyl methyl, piperazinyl methyl, morpholino methyl, morpholino ethyl, morpholino propyl, thiomorpholino methyl, thiomorpholino propyl, 4-methoxybenzenesulfonyl methyl, 3-(4-methoxybenzenesulfonyl)amino propyl, 3-hydroxy, amino, 3-phenoxy propyl, 2-phenyl ethyloxy, (4-butoxybenzenesulfonyl)methyl, methyl-3-(1,5,5-trimethylhydantoin), methyl-3-(1-butyl-5,5-dimethylhydantoin), (4-methoxybenzenesulfonyl)methyl, (4-chlorobenzenesulfonyl)-methyl, (4-bromobenzenesulfonyl)methyl, (n-butylsulfonyl)methyl, (n-octylsulfonyl)-methyl, 3-(4-methoxybenzenesulfonyl)propyl, (4-methylbenzenesulfonyl)methyl, (benzenesulfonyl)methyl, methyl-3-(1-methylhydantoin), methyl-3-(1-butylhydantoin) and methyl-3-(5,5-dimethylhydantoin). 8. A compound of claim 1 wherein R.sub.2 is selected from the group consisting of (4-methoxybenzenesulfonyl)methyl, (4-chlorobenzenesulfonyl)-methyl, (4-bromobenzenesulfonyl)methyl, (n-butylsulfonyl)methyl, (n-octylsulfonyl)-methyl, 3-(4-methoxybenzenesulfonyl)propyl, (4-methylbenzenesulfonyl)methyl, (benzenesulfonyl)methyl, methyl-3-(1-methylhydantoin), methyl-3-( 1-butylhydantoin) and methyl-3-(5,5-dimethylhydantoin). 9. A compound of claim 1 which is (1) N-hydroxy 2-[(4-methoxybenzenesulfonyl) methyl]-3-phenyl-propionamide, (2) N-hydroxy 2-[(benzenesulfonyl)methyl]-3-phenyl-propionamide, (3) N-hydroxy 2-[(benzenesulfonyl)methyl]-propionamide, (4) N-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-methoxybenzenesulfonyl )-propionamide, (5) N-hydroxy-2-[(4-chlorobenzenesulfonyl)methyl]-3-(4-chlorobenzenesulfonyl)- propionamide, (6) N-hydroxy-2-[(4-bromobenzenesulfonyl)methyl]-3-(4-bromobenzenesulfonyl)-pr opionamide, (7) N-hydroxy-2-[(n-butylsulfonyl)methyl]-3-(n-butylsulfonyl)-propionamide, (8) N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(n-octylsulfonyl)-propionamide, (9) N-hydroxy-2-[(4-methylbenzenesulfonyl)methyl]-3-(4-methylbenzenesulfonyl)- propionamide, (10) N-hydroxy-2-[(benzenesulfonyl)methyl]-3-(benzenesulfonyl)-propionamide, (11) N-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-5-(4-methoxybenzenesulfonyl )-pentanamide, (12) N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(4-methoxybenzenesulfonyl)-propion amide, (13) N-hydroxy-2-[methyl-3-(1-methylhydantoin)]-3-(4-methoxybenzenesulfonyl)-pr opionamide, (14) N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-butoxybenzenesulfonyl)-prop ionamide, (15) N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-methoxybenzenesulfonyl)-pro pionamide, (16) N-hydroxy-2-[methyl-3-(5,5-dimethylhydantoin)]-3-(4-methoxybenzene-sulfony l)-propionamide, (17) (+)-N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(4-methoxybenzenesulfonyl)-pro pionamide, (18) (-)-N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(4-methoxybenzenesulfonyl)-pro pionamide, (19) (+)-N-hydroxy-2-[methyl-3-(1-methylhydantoin)]-3-(4-methoxybenzenesulfonyl )-propionamide, (20) (-)-N-hydroxy-2-[methyl-3-(1-methylhydantoin)]-3-(4-methoxybenzenesulfonyl )-propionamide, (21) (+)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-butoxybenzenesulfonyl)- propionamide, (22) (-)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-butoxybenzenesulfonyl)- propionamide, (23) (+)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-methoxybenzenesulfonyl) -propionamide, (24) (-)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-methoxybenzenesulfonyl) -propionamide, (25) (+)-N-hydroxy-2-[methyl-3-(5,5-dimethylhydantoin)]-3-(4-methoxybenzenesulf onyl)-propionamide, or (26) (-)-N-hydroxy-2-[methyl-3-(5,5-dimethylhydantoin)]-3-(4-methoxybenzenesulf onyl)-propionamide. 10. A compound of claim 1 which is (1) N-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-3-(4-methoxybenzenesulfonyl )-propionamide, (2) N-hydroxy-2-[(4-chlorobenzenesulfonyl)methyl]-3-(4-chlorobenzenesulfonyl)- propionamide, (3) N-hydroxy-2-[(4-bromobenzenesulfonyl)methyl]-3-(4-bromobenzenesulfonyl)-pr opionamide, (4) N-hydroxy-2-[(n-butylsulfonyl)methyl]-3-(n-butylsulfonyl)-propionamide, (5) N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(n-octylsulfonyl)-propionamide, (6) N-hydroxy-2-[(4-methylbenzenesulfonyl)methyl]-3-(4-methylbenzenesulfonyl)- propionamide, (7) N-hydroxy-2-[(benzenesulfonyl)methyl]-3-(benzenesulfonyl)-propionamide (8) N-hydroxy-2-[(4-methoxybenzenesulfonyl)methyl]-5-(4-methoxybenzenesulfonyl )-pentanamide, (9) N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(4-methoxybenzenesulfonyl)-propion amide, (10) N-hydroxy-2-[methyl-3-(1-methylhydantoin)]-3-(4-methoxybenzenesulfonyl)-pr opionamide, (11) N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-butoxybenzenesulfonyl)-prop ionamide, (12) N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-methoxybenzenesulfonyl)-pro pionamide, (13) N-hydroxy-2-[methyl-3-(5,5-dimethylhydantoin)]-3-(4-methoxybenzenesulfonyl )-propionamide, (14) (+)-N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(4-methoxybenzenesulfonyl)-pro pionamide, (15) (-)-N-hydroxy-2-[(n-octylsulfonyl)methyl]-3-(4-methoxybenzenesulfonyl)-pro pionamide, (16) (+)-N-hydroxy-2-[methyl-3-(1-methylhydantoin)]-3-(4-methoxybenzenesulfonyl )-propionamide, (17) (-)-N-hydroxy-2-[methyl-3-(1-methylhydantoin)]-3-(4-methoxybenzenesulfonyl )-propionamide, (18) (+)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-butoxybenzenesulfonyl)- propionamide, (19) (-)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-butoxybenzenesulfonyl)- propionamide, (20) (+)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-methoxybenzenesulfonyl) -propionamide, (21) (-)-N-hydroxy-2-[methyl-3-(1-butylhydantoin)]-3-(4-methoxybenzenesulfonyl) -propionamide, (22) (+)-N-hydroxy-2-[methyl-3-(5,5-dimethylhydantoin)]-3-(4-methoxybenzenesulf onyl)-propionamide, or (23) (-)-N-hydroxy-2-[methyl-3-(5,5-dimethylhydantoin)]-3-(4-methoxybenzenesulf onyl)-propionamide. 11. A method of inhibiting excess matrix metalloproteinase which comprises administering to a patient in need thereof an effective amount of a compound of claim 1. 12. The method of claim 11 wherein matrix metalloproteinases comprises stromelysin, collagenase, and gelatinase. 13. A method of treating a human suffering from or susceptible to diseases involving connective tissue degradation which comprises administering to a patient in need thereof an effective amount of a compound of claim 1. 14. The method of claim 13 wherein the diseases related to connective tissue degradation are osteoarthrits, rheumatoid arthritis, septic arthritis, osteopenias, steoporosis, tumor metastasis, periodontitis, gingivitis, corneal epidermal ulceration, or gastric ulceration. 15. The method of claim 11 wherein the effective amount of the compound of claim 1 is administered orally, parenterally, or topically in a pharmaceutical composition. 16. The method of claim 13 wherein the effective amount of the compound of claim 1 is administered orally, parenterally, or topically in a pharmaceutical composition. 17. The method of claim 11 or 13 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day. 18. A pharmaceutical composition which comprises an amount of the compound of claim 1 effective to inhibit excess matrix metalloproteinase and a pharmaceutically acceptable carrier.

Details for Patent 5,847,153

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29